AbbVie Inc. (ABBV) News

AbbVie Inc. (ABBV): $157.54

-0.48 (-0.30%)

POWR Rating

Component Grades













Filter ABBV News Items

ABBV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABBV News Highlights

  • For ABBV, its 30 day story count is now at 21.
  • Over the past 19 days, the trend for ABBV's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • The most mentioned tickers in articles about ABBV are DRUG, MG and CRL.

Latest ABBV News From Around the Web

Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

Who Are Pfizer's (PFE) Main Competitors?

Pfizer's biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.

Yahoo | March 25, 2023

Better Buy: AbbVie vs. Johnson & Johnson

AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.

Yahoo | March 25, 2023

Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951

Yahoo | March 24, 2023

The price of Humira's biosimilars can uncloak the secret villain of US drug pricing

Pharmaceutical giant AbbVie was able to delay competition to its blockbuster arthritis drug, Humira, into the US market for many years. But Americans can finally choose from one of several arthritis biosimilars, as generics for complex molecule drugs are known.

Yahoo | March 23, 2023

2 High-Yield Dividend Stocks You Won't Regret Buying Right Now

High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. Which high-yield dividend stocks are worth buying right now? Read on to find out more about these above-average passive income opportunities.

Yahoo | March 23, 2023

AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate

In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951.

Yahoo | March 23, 2023

AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

AbbVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ®, 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE).1 The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30

Yahoo | March 23, 2023

Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis.1 In the study, 20.3% of patients receiving risankizumab achieved clinical remission compared to 6.2% of patients receiving plac

Yahoo | March 23, 2023

AbbVie (NYSE:ABBV) shareholders have earned a 37% CAGR over the last three years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...

Yahoo | March 23, 2023

Use These 3 Strategies to Make $1,000 in Passive Income Per Year

Passive income is a holy grail for many investors, but it's a lot easier to want it than it is to make enough of it from your holdings. Buying shares of any old dividend stock simply won't do; you need a strategy that's right for your goals and your means. Dollar-cost averaging is a slow and safe way to build up a position in a dividend stock.

Yahoo | March 23, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6703 seconds.